Shares of Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) continued rising by soaring $1.75 to close at $10.20 after the FDA approved the biopharmaceutical's schizophrenia treatment Fanapt last week.
Vanda Continues To Rise
May 11, 2009 at 17:17 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.